ARTICLE

A systematic review of cancer GWAS and candidate gene meta-analyses reveals limited overlap but similar effect sizes

Christine Q Chang¹, Ajay Yesupriya², Jessica L Rowell³, Camilla B Pimentel⁴, Melinda Clyne⁴, Marta Gwinn⁵, Muin J Khoury^{1,6}, Anja Wulf⁶ and Sheri D Schully^{*,1}

Candidate gene and genome-wide association studies (GWAS) represent two complementary approaches to uncovering genetic contributions to common diseases. We systematically reviewed the contributions of these approaches to our knowledge of genetic associations with cancer risk by analyzing the data in the Cancer Genome-wide Association and Meta Analyses database (Cancer GAMAdb). The database catalogs studies published since January 1, 2000, by study and cancer type. In all, we found that meta-analyses and pooled analyses of candidate genes reported 349 statistically significant associations and GWAS reported 269, for a total of 577 unique associations. Only 41 (7.1%) associations were reported in both candidate gene meta-analyses and GWAS, usually with similar effect sizes. When considering only noteworthy associations (defined as those with false-positive report probabilities ≤ 0.2) and accounting for indirect overlap, we found 202 associations, with 27 of those appearing in both meta-analyses and GWAS. Our findings suggest that meta-analyses of well-conducted candidate gene studies may continue to add to our understanding of the genetic associations in the post-GWAS era.

European Journal of Human Genetics (2014) 22, 402–408; doi:10.1038/ejhg.2013.161; published online 24 July 2013

Keywords: GWAS; candidate gene studies; meta-analysis; cancer

INTRODUCTION

Candidate gene association studies have been widely used to study genetic susceptibility to complex diseases, including cancer.¹ Critics of candidate gene studies have pointed to non-replication of results, false positives, insufficient sample sizes, and limited prior knowledge of biologically relevant candidate genes.² These concerns have prompted the use of systematic reviews, especially meta-analyses of multiple studies, to minimize false-positive associations and assess the credibility of findings.³ In recent years, genome-wide association studies (GWAS) have greatly accelerated the pace of discovery and found many novel genetic associations that were not anticipated by the candidate gene approach.4,5 Associations discovered by GWAS raise additional questions, particularly because observed effects are typically very small.⁶ Furthermore, the implicated SNPs represent markers that require further investigation to identify causal variants,⁷ although this may become less of a problem as methods for finemapping associations improve.

A critical evaluation of a decade's worth of association studies is warranted as the next phase of cancer genetics research unfolds. In the present analysis, we used the data available in a 2008 paper published by Dong *et al*⁸ and in the Cancer Genome-wide Association and Meta Analyses database (Cancer GAMAdb)⁹ to complete a systematic review of genetic associations in cancer GWAS and meta-analyses and pooled analyses published over an 11-year period, from 2000–2011.

MATERIALS AND METHODS

Cancer GAMAdb

To help consolidate the vast amount of information from both candidate gene and GWAS of cancer, the Centers for Disease Control and Prevention's (CDC) Office of Public Health Genomics and the National Cancer Institute's Division of Cancer Control and Population Sciences launched the Cancer GAMAdb in 2010.9 This continuously updated database catalogs published GWAS and meta-analyses and pooled analyses that have evaluated associations of genetic polymorphisms and cancer risk since January 1, 2000. Cancer GAMAdb builds on a published data set by Dong *et al*,⁸ which encompassed meta-analyses and pooled analyses of genetic polymorphisms, and cancer risk published until March 15, 2008. Associations in the database published after that date have been identified using the Human Genome Epidemiology (HuGE) Navigator database¹⁰ and the National Human Genome Research Institute (NHGRI) GWAS catalog.¹¹ The Centers for Disease Control and Prevention's HuGE Navigator is a continuously updated knowledge base in HuGE.¹⁰ The NHGRI GWAS catalog extracts data from GWAS publications.¹¹ Genetic associations with cancer are selected from these two databases for curation in the Cancer GAMAdb. Data describing the association(s)-including study population, minor allele frequencies, and effect sizes-are manually extracted from each article and entered into the Cancer GAMAdb. The current analysis is based on the data that were included in Cancer GAMAdb as of February 26, 2011.


Selection criteria

We selected genetic associations for our analysis according to the schema in Figure 1. We excluded meta-analyses and pooled analyses with *P*-values of odds ratios (OR) \geq 0.05 (if *P*-values were not reported, we calculated *P*-values as

¹Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA; ²Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ³Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; ⁴University of Massachusetts Medical School, Graduate School of Biomedical Sciences, Clinical and Population Health Research Program, Worcester, Massachusetts, USA; ⁵McKing Consulting Corporation, Atlanta, Georgia, USA; ⁶Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

^{*}Correspondence: Dr S Schully, Division of Cancer Control and Population Sciences, National Cancer Institute, 9609 Medical Center Drive Rockville, MD 20850, USA. Tel: + 240 276 6936; E-mail: schullys@mail.nih.gov

Received 14 November 2012; revised 5 April 2013; accepted 19 June 2013; published online 24 July 2013





described in Dong *et al*⁸). We excluded meta-analyses with fewer than 500 total cases or based on less than two studies for the meta-analyses and pooled analyses (or if either was unknown). We standardized the gene names with the Human Genome Organisation gene symbol and the National Center for Biotechnology Information Entrez Gene GeneID, as well as the RefSNP accession ID (rs numbers) for variant names where possible. To fill in the missing gene names, we searched by variant name using HuGE Navigator's Variant Name Mapper and the UCSC Genome Browser and collected region information if the variant was intergenic.

Our analysis was limited to genetic associations with incident cancer of specified type; we excluded associations with other outcomes (eg, all cancers, precursor lesions, biomarkers, or survival). Associations with circulating levels of *IGF1*; human lymphocyte antigen (*HLA*) markers; high-penetrance genetic markers (eg, *APC*, *BRCA1*); and associations with *HRAS1* (which have been questioned because of flawed genotyping methods) were also excluded.

When an association had been examined in multiple meta-analyses, we included only the most recent publication. We gave priority to the most recently reported overall association with a particular variant; however, if no significant overall association had been reported, we included the most recent subgroup-specific association. If a publication reported multiple significant contrasts (ie, results based on different genetic models) for the same variant, we included the contrast with the smallest *P*-value. When significant

403

associations were found with the same variant in both meta-analyses and GWAS, we checked to be sure that they compared the same contrasts. Associations with combinations of two or more variants were considered unique, even if associations with the individual variants were also reported.

GWAS data were restricted to studies of incident cancer published before February 26, 2011. Studies were identified from the HuGE Navigator and checked against the NHGRI GWAS catalog to ensure completeness. In some instances, we checked the original publication for additional information; if we noticed data discrepancies between the GWAS catalog and the original paper, we used the data from the original paper. GWAS that included meta-analyses were classified as GWAS. Associations for which variants were not specified were excluded from analysis. When multiple GWAS reported the same association, we included only the most recently published study in our analysis.

Analysis strategy

Our analysis considered the extent to which associations reported in metaanalyses and GWAS overlapped. When both types of studies reported associations with the same variant, we called the overlap direct. When they reported associations with variants separated by less than 1 million base pairs, we called the overlap indirect. In an additional analysis, we also examined noteworthy associations, which we defined as those with false-positive report probabilities (FPRP) ≤ 0.2 , a stringent threshold suggested by Wacholder *et al*,¹² and used in the analysis by Dong *et al*.⁸ We calculated FPRPs at two levels of prior probability and at two levels of association (OR 1.5 and OR 1.2). As in the analysis by Dong *et al*,⁸ we chose to evaluate the associations using a low-prior probability of 0.001 (expected for a candidate gene) and a very low-prior probability of 0.000001 (expected for a random SNP). An association was considered noteworthy if it passed the FPRP threshold in one or more of these four categories.

RESULTS

Significant associations are summarized in Table 1 by the cancer site and the study type.

Meta- and pooled analyses

We identified 5131 gene-variant associations with incident cancer from 386 meta-analyses and pooled analyses published after the review by Dong *et al* review. We excluded 3828 (74.6%) associations because their reported *P*-values were ≥ 0.05 ; 1026 more were excluded for reasons listed in Figure 1. After applying all exclusion criteria, we found 277 significant associations; the review by Dong *et al* included 98 significant associations. Twenty-six (7.4%) of these were also found in meta-analyses published since the paper by Dong *et al*. Thus, there were 349 unique variant-cancer associations in all, involving 264 genes (76 with more than one associated variant) and spanning 25 different cancer types.

The largest number of candidate gene associations was found for breast cancer (n = 80) followed by prostate cancer (n = 53). Significant associations from meta-analyses and pooled analyses of candidate genes are listed in Supplementary Table 1.

Genome-wide association studies

We identified 4994 GWAS associations from 825 citations. We excluded 4645 associations with outcomes other than incident cancer and 80 for other reasons listed in Figure 1. In the end, there were 269 unique associations in 223 different genes with 21 different cancer types. The largest number of GWAS associations was found for prostate cancer (n = 56) followed by breast cancer (n = 36). Variants from GWAS are listed in Supplementary Table 2.

	MA	qa	<i>GWAS</i> ^b		
Cancer Site	Variants ^c	Genes ^d	Variants ^c	Genes ^d	
Bladder	15	14	10	10	
Blood-related (ALL, MCL, NHL)	1	1	_	_	
Breast	80	59	36	30	
Cervical	4	4	_	_	
Colorectal	30	23	17	14	
Endometrial	2	1	_	_	
Esophageal	9	9	4	4	
Gastric	21	17	2	2	
Genitourinary	2	2	_	_	
Glioma	18	13	9	8	
Head and neck	14	11	_	_	
Hepatocellular	8	4	4	6	
Hodgkin lymphoma	_	_	4	3	
Laryngeal	2	2	_	_	
Leukemia	4	4	32	27	
Lung	32	23	25	22	
Meningioma	1	1	_	_	
Myeloproliferative	_	_	1	1	
Nasopharyngeal	4	3	6	6	
Neuroblastoma	_	_	5	3	
Non-Hodgkin lymphoma	10	8	2	2	
Oral	1	1	_	_	
Ovarian	14	12	10	10	
Pancreatic	_	_	21	21	
Prostate	53	40	56	35	
Renal cell	_	_	3	3	
Skin	20	8	8	7	
Testicular	_	_	12	10	
Thyroid	_	_	2	2	
Upper aero-digestive tract	2	2	_	_	
Upper aero-digestive tract and lung	1	1	_	_	
Urothelial	1	1	_	_	
Total	349	264	269	223	

Abbreviations: ALL, adult lymphoblastic leukemia; GWAS, genome-wide association studies; MA, meta-analyses or pooled analyses; MCL, myeloid cell leukemia; NHL, non-Hodgkin lymphoma.

^aTotal significant associations reported in previous systematic review of meta-analyses (Dong *et aP*) and meta-analyses and pooled data of individual studies published from 20 March 2008 through 26 February 2011. Meta-analyses were defined as those of candidate gene studies. Significance threshold was 0.05.

 $^{\rm b} {\rm From ~GWAS}$ catalog. Excludes variants that were not reported. GWAS with meta-analyses included were considered GWAS. Significance threshold was $1\times 10^{-5}.$

Some variants may be linked to one another due to proximity. Associations with combinations of two or more variants were considered unique, even if listed standalone variants were also reported.

dIntergenic regions used if no gene provided by paper or associated with variant.

Combined

The combined results from candidate gene meta-analyses and GWAS included 577 unique associations of 446 different genes or chromosomal regions with 32 cancers. When we considered only direct overlap, we found 41 associations that had been reported in both meta-analyses and GWAS (Supplementary Table 3). The largest number of such associations was with prostate cancer (n = 25), followed by breast cancer (n = 8).

When we restricted our analysis to noteworthy associations (calculated FPRPs of ≤ 0.2 in either prior probability or OR) and allowed for direct and indirect overlap (both within and between study types), we found 202 unique associations in all. Of these,

Table 2 Number of noteworthy associations reported in candidate gene meta-analyses and pooled analyses and GWAS, accounting for direct and indirect overlap, by cancer site

		MA ^a				
Cancer site	Dong, et al ^b	Subsequent MA ^c	Total	<i>GWAS</i> ^d	Overlap	Total unique
Bladder	2	2	3	10	3	10
Blood-related	0	1	1	0	0	1
Breast	3	13	15	14	7	22
Colorectal	1	5	6	14	1	19
Endometrial	0	1	1	0	0	1
Esophageal	0	5	5	3	1	7
Gastric	1	3	4	2	0	6
Glioma	0	0	0	5	0	5
Head and neck	0	1	1	0	0	1
Hepatocellular	0	1	1	4	0	5
Hodgkin's	0	0	0	3	0	3
lymphoma						
Leukemia	2	0	2	25	0	27
Lung	3	6	8	10	2	16
Myeloproliferative	0	0	0	1	0	1
Nasopharyngeal	0	1	1	4	0	5
Neuroblastoma	0	0	0	3	0	3
Non-Hodgkin's	0	1	1	2	0	3
lymphoma						
Ovarian	0	0	0	8	0	8
Pancreatic	0	0	0	16	0	16
Prostate	1	15	16	21	12	25
Renal cell	0	0	0	3	0	3
Skin	0	1	1	7	1	7
Testicular	0	0	0	6	0	6
Thyroid	0	0	0	2	0	2
Total	13	56	66	163	27	202

Abbreviations: GWAS, genome-wide association studies; MA, meta- or pooled analyses ^aNoteworthy associations from meta- and pooled analyses of candidate gene studies. ^bReported in previous systematic review of meta-analyses (Dong *et al*^{β}).

^dFrom GWAS catalog. Excludes variants that were not reported in meta-analyses (Doing et al.). ^dFrom GWAS catalog. Excludes variants that were not reported. GWAS with meta-analyses included were considered GWAS.

66 were from candidate gene studies and 163 were from GWAS; 27 (13%) of these were found in both meta-analyses and GWAS (Table 2). We were unable to evaluate 38 GWAS associations for noteworthiness because the original publications did not report ORs and CIs. Allowing for indirect overlap, we found the largest numbers of noteworthy associations in leukemia (n = 27), followed by prostate cancer (n = 25). Noteworthy associations that were found only in meta-analyses (n = 39) are listed in Table 3. All noteworthy associations are included in Supplementary Table 4.

Meta-analyses and GWAS that examined the same variants (direct overlap) reported very similar ORs (Figure 2). All but three associations had ORs between 1.00 and 1.50. The largest effect sizes were observed for esophageal cancer and *ALDH2* rs671 (heterozygous) in both meta-analysis (OR = 2.52) and GWAS (OR = 3.48).

DISCUSSION

We summarized the principal findings from a decade of published genetic associations with incident cancer. We found that metaanalyses and pooled analyses of candidate gene studies had identified 349 statistically significant associations and GWAS identified 269. Very few associations were found in both groups; however, variant-cancer associations that were reported in both meta-analyses and GWAS had comparable effect sizes.

When we stratified on the basis of cancer type, there was considerable variation in the relative numbers of associations identified by meta-analyses and GWAS. For example, meta-analysis of candidate genes identified 80 breast cancer variants, versus 36 identified by GWAS. In contrast, meta-analysis found only four leukemia variants, compared with 32 identified by GWAS. The difference in the number of significant associations between the meta-analyses of candidate gene studies and GWAS could reflect variations in research interest, prevalence, or underlying knowledge of pathogenesis of different cancers.

Candidate gene studies and GWAS use different thresholds to define statistical significance. We used a P-value threshold of 0.05 for candidate gene studies and 1.0×10^{-5} for GWAS; the latter is used by the NHGRI GWAS Catalog, although 5×10^{-8} is more widely accepted in the literature today. These thresholds are consistent with those used in the original studies; however, it has been suggested that P = 0.05 may be too lenient for candidate genes studies¹³ and $P = 5 \times 10^{-8}$ may be too stringent for GWAS.^{14,15} If this is true, then differences in the number of significant associations could also reflect an excess of false-positive findings from candidate gene studies¹³ and an excess of false negatives from GWAS.¹⁴ It has been suggested that in GWAS, where false negatives outnumber false positives, lowering the significance threshold to 10^{-7} would yield mostly genuine discoveries.¹⁵ Others have suggested that 10⁻⁷ be held as the criterion for early commercial genotyping arrays, but the standard 5×10^{-8} for current or merged commercial arrays.¹⁶ Falsepositive findings due to too lenient thresholds may be particularly pertinent for candidate gene studies that examine several variants and do not correct for multiple testing.

We identified noteworthy associations by calculating FPRPs as described by Wacholder *et al.*¹² The FPRP for a genetic association takes into account not only the observed *P*-value but also the prior probability of the association and the statistical power of the test. We found 189 noteworthy associations in addition to the 13 previously reported by Dong *et al.*⁸ Most of these noteworthy associations were identified in GWAS; however, 39 were found exclusively in meta-analyses of candidate gene associations.

Meta-analysis of candidate gene association studies diminishes, but does not entirely exclude, random error and bias as causes of falsepositive associations. GWAS also have challenges; in particular, the actual fraction of the genome interrogated in a GWAS varies with the genotyping platform and study population.¹⁷ Although imputation methods may help increase the genomic coverage, they are not perfect, especially for variants of lower frequency. For example, in an attempt to unify candidate gene and GWAS approaches in asthma, Michel *et al*¹⁸ found that GWAS coverage was insufficient for many asthma candidate genes.

More in-depth analysis in future studies could further elucidate why 39 candidate gene associations did not reproduce in GWAS. Insufficient power due to the limited ability of GWAS to detect rare variants may have a role. Candidate gene studies are not suited for the study of exceptionally rare variants either, not without incredibly large sample sizes. Uncommon variants, however, which include *CHEK2*, may still have frequencies too low to be detected through GWAS.⁴ The *CHEK2* 1100delC mutation, an established genetic risk factor for breast cancer, was found in 0.7% of cases and 0.4% of controls in a Swedish study population.¹⁹ Despite many GWAS conducted in breast cancer, *CHEK2* has not passed the 1×10^{-5} threshold (as reported by the NHGRI GWAS Catalog).¹¹ It is important to add, however, that 406

Table 3 Noteworthy associations only found in meta- and pooled analyses of candidate gene studies

Source/ Locus PMID ^a Blood-related cancer 11q13.3 1884302 Breast cancer 2q13 2043719 2q33.1 Dong 1962967 2q33.2 2092033 5p12 2119447 17q22 2119447 17q22 21984352 22q12.1 Dong 2001223 22q12.1 Dong 2043719 2043719 20q33.2 2092033 5p12 2119447 17q22 2119447 1962967 2030123 22q12.1 Dong 2001223 22q12.1 Dong Colorectal cancer 192450 2050310 19913.2 2001223 22q11.23 Dong 201243 2080644 1612.2 2036014 17p13.1 2082743 2036014 17p13.1 2082743 Gastric cancer 1984358 19913.32 2098158 Hepatocellular carcinoma 12q15 2124052 Lung cancer 1912449 22q11.23 100q2	1D ^a 3022 7198 ng 9679 0330 4473 4473 ng 3929	Gene/region CCND1 IL1B CASP8 CTLA4 MRPS30 COX11/	Variant rs17852153 rs1143627 rs1045485 rs231775	OR 1.62 1.4	95% CI lower 1.28	95% CI upper 2.05	P-value ^b	0.001 and OR 1.5	0.000001 and OR 1.5	0.001 and OR 1.2	0.000001
Blood-related cancer 11q13.3 1884302 Breast cancer 2q13 2043719 2q33.1 Dong 1962967 2q33.2 2092033 5p12 2119447 17q22 2119447 17q22 2119447 19q13.2 Dong 20q13.2 1982392 22q12.1 Dong 20q13.2 1984368 12q15 2050310 19q13.2 2001223 22q11.23 Dong 20q13.2 1984358 12q15 2050310 19q13.2 2001223 22q11.23 Dong 201223 22q11.23 Dong Endometrial cancer 1912450 2050310 194250 Esophageal cancer 1031.1 2130421 4q23 2080644 16q12.2 2036014 17713.1 2082743 2036014 Gastric cancer 1p36.22 Dong 20413.3 1977735 19q13.32 2098156 4413.3 1977735 19q13.32 2098156 Hepatocellular carcinoma 12q15 2124052 22412.23 1003 22q11.23	3022 7198 9679 0330 1473 1473 19 3929	CCND1 IL1B CASP8 CTLA4 MRPS30	rs17852153 rs1143627 rs1045485	1.62 1.4			P-value ^b	OR 1.5	OR 1.5	0012	and OD 1 (
11q13.3 1884302 Breast cancer 2q13 2043719 2q33.1 Dong 1962967 2q33.2 2092033 5p12 2119447 19q13.2 Dong 202013.2 21984362 20q13.2 1982392 22q12.1 Dong 20q13.2 1984566 11q22.2 1984656 11q22.2 1984656 11q22.2 198458 12q15 2050310 10913.2 2001223 22q11.23 Dong 201223 22q11.23 Dong Endometrial cancer 15q21.2 1912450 2050310 15q21.2 1912450 2036014 4123 2080644 16q12.2 2036014 413.3 197735 19q13.32 2098155 Head and neck cancers 11q22.2 1984358 Hepatocellular carcinoma 12q15 2124052 Leukemia 1913.3 Dong 203138 12q15 2124052 2036014 1913.3 Dong 1911638 10q26.3 2003138 12q15 Don	7198 9679 9330 1473 1473 19 3929	IL1B CASP8 CTLA4 MRPS30	rs1143627 rs1045485	1.4	1.28	2.05				UN 1.2	and OR 1.2
Breast cancer $2q13$ 2043719 $2q33.1$ Dong 1962967 $2q33.2$ 2092033 $5p12$ 2119447 $17q22$ 2119447 $17q22$ 2119447 $19q13.2$ Dong $20q13.2$ 1982392 $22q12.1$ Dong Colorectal cancer $1p26.22$ $12q15$ 2050310 $12q15$ 2050310 $19q13.2$ 2001223 $22q11.23$ Dong Endometrial cancer $15q21.2$ $15q21.2$ 1912450 Sophageal cancer $1q31.1$ $1q31.1$ 20300144 $4q23$ 20360144 $16q12.2$ Dong $2q13$ 20360144 $19q13.32$ 2098155 Head and neck cancers $11q22.2$ $11q22.2$ 1984358 $4epatocel/lular carcinoma$ $12q15$ $12q15$ 2124052 eukemia $1p13.3$ Dong $11q22.2$ 1984358 </td <td>7198 9679 9330 1473 1473 19 3929</td> <td>IL1B CASP8 CTLA4 MRPS30</td> <td>rs1143627 rs1045485</td> <td>1.4</td> <td>1.28</td> <td>2 05</td> <td></td> <td></td> <td></td> <td></td> <td></td>	7198 9679 9330 1473 1473 19 3929	IL1B CASP8 CTLA4 MRPS30	rs1143627 rs1045485	1.4	1.28	2 05					
2q13 2043719 2q33.1 Dong 1962967 2q33.2 2092033 5p12 2119447 17q22 2119447 17q22 2119447 19q13.2 Dong 20q13.2 1982392 22q12.1 Dong 20q13.2 1982392 22q12.1 Dong Colorectal cancer 1 1p26.22 1984656 11q22.2 1984358 12q15 2050310 12q15 2050310 19q13.2 2001223 22q11.23 Dong Endometrial cancer 1 15q21.2 1912450 Esophageal cancer 1 1p36.22 Dong 2q13 2036014 16q12.2 2036014 4q13.3 1977735 19q13.32 2098155 Aead and neck cancers 1 11q22.2 1984358 Aepatocellular carcinoma 1 12q15 2124052 eukemia 1	ng 9679 0330 1473 1473 1473 ng 3929	CASP8 CTLA4 MRPS30	rs1045485			2.00	0.0001	0.184	0.996	0.904	1.000
2q33.1 Dong 1962967 2q33.2 2092033 5p12 2119447 17q22 2119447 19q13.2 Dong 20q13.2 2q2q12.1 Dong 20lorectal cancer 1982392 12q12.1 Dong 20lorectal cancer 1984358 12q15 2050310 12q15 2050310 19q13.2 2001223 22q11.23 Dong Endometrial cancer 15q21.2 1931.1 2130421 4q23 2080644 16q12.2 2036014 4q13.3 197735 19q13.32 2098155 fead and neck cancers 11q22.2 11q22.2 1984358 depatocellular carcinoma 12q15 12q15 2124052 eukemia 1913.3 1p13.3 Dong 22q11.23 Dong 10q26.3 2003138 12q15 Dong 16q12.2 2036014	ng 9679 0330 1473 1473 1473 ng 3929	CASP8 CTLA4 MRPS30	rs1045485								
1962967 2q33.2 2092033 5p12 2119447 17q22 2119447 19q13.2 Dong 20q13.2 1982392 22q12.1 Dong Colorectal cancer 1p26.22 1q21.2 1984656 1q22.2 1984656 1q22.2 1984656 1q21.5 2050310 19q13.2 2001223 22q11.23 Dong Endometrial cancer 1 15q21.2 1912450 Esophageal cancer 1 1q31.1 2130421 4q23 2080644 16q12.2 2036014 16q12.2 Dong 2q13 2036014 16q13.3 197735 19q13.32 2098155 Head and neck cancers 1 11q22.2 1984358 Hepatocellular carcinoma 12q15 12q15 2124052 Leukemia 1 1213.3 Dong </td <td>9679 0330 1473 1473 1473 19 3929</td> <td>CTLA4 MRPS30</td> <td></td> <td></td> <td>1.17</td> <td>1.67</td> <td>1.8E-04</td> <td>0.191</td> <td>0.996</td> <td>0.809</td> <td>1.000</td>	9679 0330 1473 1473 1473 19 3929	CTLA4 MRPS30			1.17	1.67	1.8E-04	0.191	0.996	0.809	1.000
2q33.2 2092033 5p12 2119447 17q22 2119447 19q13.2 Dong 20q13.2 1982392 22q12.1 Dong Colorectal cancer 1p26.22 1q21.2 1984358 12q15 205010 19q13.2 2001223 22q11.23 Dong Endometrial cancer 15q21.2 15q21.2 1912450 Esophageal cancer 1931.1 17p13.1 2080644 16q12.2 2036014 16q12.2 Dong 2q13 2036014 17p13.1 2082743 Gastric cancer 1p36.22 Dong 1p31.3 197735 19q13.32 2098155 Head and neck cancers 11q22.2 11q22.2 1984358 Hepatocellular carcinoma 12q15 12q15 2124052 Leukemia 1p13.3 Dong 1p13.3 Dong 2q11.23 Dong 10q26.3 2003138	0330 1473 1473 19 19 3929	MRPS30	rs231775	0.89 0.874	0.85 0.834	0.94 0.917	5.7E-06 <i>3.9E-08</i>	0.028 <0.001	0.967 0.037	0.029 <0.001	0.967 0.038
5p12 2119447 17q22 2119447 19q13.2 Dong 20q13.2 1982392 22q12.1 Dong Dolorectal cancer 1p26.22 11q22.2 1984656 11q22.2 1984656 11q22.2 1984656 11q22.2 1984656 12q15 2050310 19q13.2 2001223 22q11.23 Dong Endometrial cancer 1912450 15q21.2 1912450 Esophageal cancer 1912450 1q31.1 2130421 4q23 2080644 16q12.2 2036014 17p13.1 2082743 Sastric cancer 1936.22 19q13.32 2098156 etad and neck cancers 11q22.2 11q22.2 1984358 tepatocellular carcinoma 12q15 12q15 2124052 eukemia 1p13.3 Dong 12q15 2036014 22q11.23 <td< td=""><td>1473 1473 ng 3929</td><td>MRPS30</td><td>10201//0</td><td>1.31</td><td>1.17</td><td>1.48</td><td>1.4E-05</td><td>0.014</td><td>0.936</td><td>0.153</td><td>0.995</td></td<>	1473 1473 ng 3929	MRPS30	10201//0	1.31	1.17	1.48	1.4E-05	0.014	0.936	0.153	0.995
19q13.2 Dong 20q13.2 1982392 22q12.1 Dong 20dorectal cancer 1926.22 11q22.2 1984358 12q15 2050310 12q15 2001223 22q11.23 Dong indometrial cancer 1 15q21.2 1912450 5sophageal cancer 1 1q31.1 2130421 4q23 2080644 16q12.2 2036014 17p13.1 2082743 Sastric cancer 1 1p36.22 Dong 2q13 2036014 4q13.3 1977735 19q13.32 2098155 fead and neck cancers 1 11q22.2 1984358 tepatocellular carcinoma 12q15 12q15 2124052 eukemia 1 1p13.3 Dong 22q11.23 Dong 10q26.3 2003138 12q15 Dong 16q12.2 2036014 19q13.31 Dong	ng 3929	COX11/	rs10941679	1.12	1.09	1.15	<1.e-30	< 0.001	< 0.001	< 0.001	< 0.001
20q13.2 1982392 22q12.1 Dong 22q12.1 Dong 22q12.1 Dong 22q12.1 Dong 22q12.1 Dong 22q12.1 Dong 22q12.2 1984358 12q15 2050310 19q13.2 2001223 22q11.23 Dong Endometrial cancer 1912450 15q21.2 1912450 Sophageal cancer 1931.1 14q23 2080644 16q12.2 2036014 16q12.2 Dong 2q13 2036014 17p13.1 2082743 Sastric cancer 1p36.22 Dong 1p31.3.2 2098155 Head and neck cancers 11q22.2 1984358 Hepatocellular carcinoma 12q15 2124052 eukemia 1p13.3 Dong 22q11.23 10q26.3 2003138 12q15 Dong 2191.23 Dong 1911638 19q13.32	3929	STXBP4	rs6504950	0.95	0.92	0.97	1.4E-06	0.001	0.583	0.001	0.583
22q12.1 Dong Colorectal cancer 1p26.22 1984656 11q22.2 1984358 12q15 2050310 19q13.2 2001223 22q11.23 Dong Endometrial cancer 1 15q21.2 1912450 Endometrial cancer 1 1q31.1 2130421 4q23 2080644 16q12.2 2036014 17p13.1 2082743 Sastric cancer 1 1p36.22 Dong 2q13 2036014 4q13.3 197735 19q13.32 2098155 fead and neck cancers 1 11q22.2 1984358 fepatocellular carcinoma 12q15 2124052 eukemia 1p13.3 Dong 22q11.23 Dong 10q26.3 2003138 12q15 Dong 2141.23 Dong 10q26.3 2036014 19q13.31 Dong		TGFB1	rs1800470	1.16	1.08	1.25	6.9E-05	0.090	0.990	0.108	0.992
Colorectal cancer 1p26.22 1984656 11q22.2 1984358 12q15 2050310 19q13.2 2001223 22q11.23 Dong Endometrial cancer 1 15q21.2 1912450 Esophageal cancer 1 1q31.1 2130421 4q23 2080644 16q12.2 2036014 17p13.1 2082743 Sastric cancer 1 1p36.22 Dong 213 2036014 4q13.3 1977735 19q13.32 2098155 Hepatocellular carcinoma 12q15 12q15 2124052 Eeukemia 1 1p13.3 Dong 22q11.23 Dong 10q26.3 2003138 12q15 Dong 12q15 Dong 16q12.2 2036014 19q13.31 Dong 19q13.32 Dong	ig	AURKA CHEK2	rs2273535 1100delC	1.23 2.4	1.1 1.8	1.37 3.2	<i>1.7E-04</i> 2.5E-09	0.143 0.004	0.994 0.782	0.338 0.678	0.998 1.000
1p26.22 1984656 11q22.2 1984358 12q15 2050310 19q13.2 2001223 22q11.23 Dong Endometrial cancer 15q21.2 15q21.2 1912450 Sophageal cancer 1912450 16q12.2 2036014 16q12.2 2036014 16q12.2 Dong 2q13 2036014 4q13.3 197735 19q13.32 2098155 Head and neck cancers 11q22.2 11q22.2 1984358 Hepatocellular carcinoma 12q15 22q11.23 Dong 10q26.3 2003138 12q15 Dong 2161.2.2 2036014 19q13.31 Dong 19q13.32 Dong 19q13.32 Dong 19q13.32 Dong 19q13.32 Dong 19q13.32 Dong 19q13.32 Dong		UNENZ	TIOOdelC	2.4	1.0	5.2	2.52-09	0.004	0.782	0.078	1.000
11q22.2 1984358 12q15 2050310 19q13.2 2001223 22q11.23 Dong Endometrial cancer 15q21.2 13q1.1 2130421 4q23 2080644 16q12.2 2036014 17p13.1 2082743 Sastric cancer 1p36.22 Dong 2q13 2036014 4q13.3 197735 19q13.32 2098155 etad and neck cancers 11q22.2 19q13.32 2098155 etad and neck cancers 11q22.2 19q13.3 Dong 22q11.23 Dong 22q11.23 Dong 22q11.23 Dong 10q26.3 2003138 12q15 Dong 12q1	FCC	MTHFR	rs1801133	0.83	0.77	0.9	6.5E-06	0.006	0.866	0.014	0.933
12q15 2050310 19q13.2 2001223 22q11.23 Dong Endometrial cancer 1912450 15q21.2 1912450 Esophageal cancer 1912450 Iq31.1 2130421 4q23 2080644 16q12.2 2036014 17p13.1 2082743 Sastric cancer 1936.22 Dong 19q13.3 1977735 19q13.32 2098155 Hepatocellular carcinoma 12q15 12q15 2124052 eukemia 1p13.3 Dong 1p13.3 Dong 22q11.23 Dong 10q26.3 2003138 12q15 2036014 19q13.31 Dong 19q13.32 Dong 19q13.32 Dong 19q13.32 Dong		MMP1	rs1799750	1.48	1.26	1.74	8.5E-06 2.1E-06	0.008	0.785	0.270	0.933
22q11.23 Dong Endometrial cancer 15q21.2 1912450 Isophageal cancer 1q31.1 2130421 1q31.1 2130421 4q23 2080644 16q12.2 2036014 17p13.1 2082743 Sastric cancer 1p36.22 Dong 2q13 2036014 4q13.3 1977735 19q13.32 2098155 Head and neck cancers 11q22.2 1984358 Hepatocellular carcinoma 12q15 2124052 Leukemia 1913.3 Dong 22q11.23 10q26.3 2003138 12q15 Dong 12q15 Dong 16q12.2 2036014 19q13.31 Dong 1911638 1911638 19q13.32 Dong 1911638 1911638		MDM2	rs2279744	0.73	0.62	0.86	1.7E-04	0.163	0.995	0.747	1.000
Endometrial cancer 15q21.2 1912450 Esophageal cancer 1q31.1 2130421 4q23 2080644 16q12.2 2036014 17p13.1 2082743 203743 Gastric cancer 1p36.22 Dong 1p36.22 Dong 2q13 2036014 4q13.3 197735 19q13.32 2098155 Head and neck cancers 11q22.2 1984358 Hepatocellular carcinoma 12q15 2124052 Eeukemia 1p13.3 Dong 1p13.3 Dong 22q11.23 Dong Lung cancer 1p13.3 1912449 22q11.23 10q26.3 2003138 12q15 Dong 12q15 Dong 16q12.2 2036014 19q13.31 Dong 1911638 1911638 19q13.32 Dong 1911638	2233	TGFB1	rs1800469	1.62	1.3	2.02	1.8E-05	0.069	0.987	0.826	1.000
15q21.2 1912450 Esophageal cancer 1q31.1 2130421 4q23 2080644 16q12.2 2036014 17p13.1 2082743 Sastric cancer 1p36.22 Dong 1p36.22 Dong 2q13 2036014 4q13.3 1977735 19q13.32 2098155 Head and neck cancers 11q22.2 11q22.2 1984358 Hepatocellular carcinoma 12q15 22q11.23 Dong 22q11.23 Dong 10q26.3 2003138 12q15 Dong 16q12.2 2036014 19q13.31 Dong 19q13.32 Dong	ng	GSTT1	GSTT1 null	1.37	1.17	1.6	8.1E-05	0.074	0.988	0.598	0.999
1q31.1 2130421 4q23 2080644 16q12.2 2036014 17p13.1 2082743 Sastric cancer 1p36.22 Dong 1p36.22 Dong 2036014 4q13.3 197735 19q13.32 2098155 Head and neck cancers 11q22.2 1984358 Hepatocellular carcinoma 12q15 2124052 Leukemia 1p13.3 Dong 12q15 2124052	1504	CYP19A1	rs749292	1.3	1.17	1.45	2.5E-06	0.002	0.714	0.032	0.971
1q31.1 2130421 4q23 2080644 16q12.2 2036014 17p13.1 2082743 Sastric cancer 1p36.22 Dong 1p36.22 Dong 2q13 2q13 2036014 4q13.3 197735 19q13.32 2098155 dead and neck cancers 11q22.2 11q22.2 1984358 depatocellular carcinoma 12q15 12q15 2124052 eukemia 1p13.3 Dong 12q15 Dong 1912449 22q11.23 10q26.3 2003138 12q15 Dong 191638 12q15 Dong 1911638 19q13.32 Dong 1911638											
4q23 2080644 16q12.2 2036014 17p13.1 2082743 Sastric cancer 1p36.22 Dong 1p36.22 Dong 2q13 2036014 4q13.3 1977735 19q13.32 2098155 Head and neck cancers 11q22.2 1984358 Hepatocellular carcinoma 12q15 2124052 Leukemia 1p13.3 Dong 12q15 2124052	4218	PTGS2	rs20417	1.45	1.23	1.71	1.0E-05	0.015	0.939	0.451	0.999
17p13.1 2082743 Sastric cancer 1p36.22 Dong 1p36.22 Dong 2q13 2036014 4q13.3 1977735 19q13.32 2098155 Head and neck cancers 11q22.2 1984358 Hepatocellular carcinoma 12q15 2124052 eukemia 1913.3 Dong 12q15 2124052 eukemia 1913.3 Dong 12q15 Dong 22q11.23 Dong 10q26.3 2003138 12q15 Dong 16q12.2 2036014 19q13.31 Dong 19q13.32 Dong	5441	ADH1B	rs1229984	1.32	1.17	1.49	7.1E-06	0.007	0.878	0.103	0.991
Gastric cancer 1p36.22 Dong 2q13 2036014 4q13.3 1977735 19q13.32 2098155 dead and neck cancers 11q22.2 11q22.2 1984358 depatocellular carcinoma 12q15 12q15 2124052 eukemia 1 1p13.3 Dong 22q11.23 Dong 10q26.3 2003138 12q15 Dong 12q15 Dong 12q15 Dong 19q13.31 Dong 19q13.32 Dong		MMP2	rs243865	0.7	0.59	0.82	9.9E-06	0.013	0.932	0.392	0.998
1p36.22 Dong 2q13 2036014 4q13.3 1977735 19q13.32 2098155 Head and neck cancers 11q22.2 11q22.2 1984358 Hepatocellular carcinoma 12q15 12q15 2124052 eukemia 1 1p13.3 Dong 22q11.23 Dong 10q26.3 2003138 12q15 Dong 16q12.2 2036014 19q13.31 Dong 19q13.32 Dong	7430	TP53	rs1042522	1.43	1.23	1.68	1.4E-05	0.018	0.950	0.451	0.999
2q13 2036014 4q13.3 1977735 19q13.32 2098155 Head and neck cancers 11q22.2 11q22.2 1984358 Hepatocellular carcinoma 12q15 12q15 2124052 eeukemia 113.3 1p13.3 Dong 22q11.23 Dong 10q26.3 2003138 12q15 Dong 16q12.2 2036014 19q13.31 Dong 19q13.32 Dong		MELLER	1001100	1 50	1 0 1	1	4 05 00	0.001	0.1.40	0.057	0.004
4q13.3 1977735 19q13.32 2098155 Head and neck cancers 11q22.2 11q22.2 1984358 Hepatocellular carcinoma 12q15 12q15 2124052 Leukemia 113.3 1p13.3 Dong 22q11.23 Dong Lung cancer 1912449 12q15 D003138 12q15 Dong 16q12.2 2036014 19q13.31 Dong 19q13.32 Dong		MTHFR MMP7	rs1801133 rs11568818	1.52 1.79	1.31 1.37	1.77 2.34	4.9E-08 <i>2.1E-05</i>	<0.001 0.173	0.140 0.995	0.057 0.923	0.984 1.000
19q13.32 2098155 Head and neck cancers 11q22.2 11q22.2 1984358 Hepatocellular carcinoma 12q15 12q15 2124052 eukemia 1113.3 12q11.23 Dong 22q11.23 Dong 10q26.3 2003138 12q15 Dong 12q15 Dong 16q12.2 2036014 19q13.31 Dong 19q13.32 Dong		IL-8	rs4073	1.363	1.199	1.527	9.2E-08	< 0.001	0.088	0.007	0.868
11q22.2 1984358 depatocellular carcinoma 12q15 12q15 2124052 eukemia 1 1p13.3 Dong 22q11.23 Dong ung cancer 1912449 12q15 2003138 12q15 Dong 12q15 Dong 12q15 Dong 12q15 Dong 12q15 Dong 16q12.2 2036014 19q13.31 Dong 19q13.32 Dong		ERCC2	rs13181	0.3	0.21	0.44	7.2E-10	0.032	0.971	0.894	1.000
12q15 2124052 eeukemia 1p13.3 Dong 12q11.23 Dong ung cancer 1p13.3 and 1912449 22q11.23 10q26.3 2003138 12q15 Dong 16q12.2 2036014 19q13.31 Dong 19q13.32 Dong	3588	MMP1	rs1799750	1.43	1.2	1.69	2.7E-05	0.037	0.974	0.577	0.999
12q15 2124052 eeukemia 1p13.3 Dong 12q11.23 Dong .ung cancer 1p13.3 and 1912449 22q11.23 10q26.3 2003138 12q15 Dong 16q12.2 2036014 19q13.31 Dong 19q13.32 Dong											
1p13.3 Dong 22q11.23 Dong .ung cancer 1912449 22q11.23 1912449 10q26.3 2003138 12q15 Dong 16q12.2 2036014 19q13.31 Dong 19q13.32 Dong)526	MDM2	rs2279744	1.57	1.36	1.8	1.0E-10	< 0.001	< 0.001	0.002	0.632
22q11.23 Dong ung cancer 1913.3 and 1912449 22q11.23 10q26.3 2003138 12q15 Dong 16q12.2 16q12.2 2036014 1911638 19q13.31 Dong 1911638 19q13.32 Dong 1911638											
ung cancer 1912449 12q11.23 1912449 10q26.3 2003138 12q15 Dong 16q12.2 2036014 19q13.31 Dong 19q13.32 Dong		GSTM1 GSTT1	GSTM1 null GSTT1 null	1.2 1.19	1.14 1.14	1.25 1.29	8.6E-15 3.5E-08	<0.001 0.023	< 0.001 0.960	<0.001 0.039	< 0.001 0.976
1p13.3 and 1912449 22q11.23 2003138 10q26.3 2003138 12q15 Dong 16q12.2 2036014 19q13.31 Dong 19q13.32 Dong	ig	03111	03111 11011	1.15	1.14	1.29	5.5L-00	0.025	0.900	0.035	0.570
22q11.23 10q26.3 2003138 12q15 Dong 16q12.2 2036014 19q13.31 Dong 1911638 19q13.32 Dong	1/07	COTMI	CSTM1 and	0.71	0.62	0.00	2 25 06	0.004	0.797	0.177	0.005
10q26.3 2003138 12q15 Dong 16q12.2 2036014 19q13.31 Dong 19q13.32 Dong	++7/	GSTM1, GSTT1	GSTM1 and GSTT1 present	0.71	0.62	0.82	3.2E-06	0.004	0.797	0.177	0.995
16q12.2 2036014 19q13.31 Dong 19q13.32 Dong	1389	CYP2E1	rs2031920	0.8	0.72	0.89	4.1E-05	0.039	0.976	0.153	0.994
19q13.31 Dong 1911638 19q13.32 Dong		MDM2	rs2279744	1.27	1.12	1.44	2.E-04	0.162	0.995	0.505	0.999
1911638 19q13.32 Dong	0147	MMP2	rs2285053 rs243865	0.72 0.55	0.61 0.48	0.85 0.63	1.0E-04 6.2E-18	0.113 <0.001	0.992 < 0.001	0.713 < 0.001	1.000 < 0.001
19q13.32 Dong	ng	XRCC1	rs25487	1.34	1.16	1.54	5.E-05	0.038	0.975	0.383	0.998
			rs3213245	1.46	1.25	1.7	1.E-06	0.002	0.633	0.159	0.995
lasopharyngeal cancer	ng	ERCC2	rs13181	1.3	1.13	1.49	2.E-04	0.143	0.994	0.566	0.999
1,100 1000000		007111	007141	1 40	1.01	1.00	1 15 05		0.005	0.000	0.000
1p13.3 1933866	3664	GSTM1	GSTM1 null	1.42	1.21	1.66	1.1E-05	0.014	0.935	0.383	0.998
<i>lon-Hodgkin lymphoma</i> 4p14 1902919	9192	TLR	rs4833103	0.75	0.64	0.87	2.E-04	0.134	0.994	0.639	0.999
Prostate cancer											
1q25.3 Dong		RNASEL	rs627928	1.27	1.13	1.44	1.E-03	0.162	0.995	0.505	0.999
8p21.2 2056431	ng	NKX3-1	rs1512268	1.17	1.12	1.23	2.E-12	< 0.001	< 0.001	<0.001	< 0.001
17q24.3 2056431 19q13.2 2056431	4319	LOC124685 LOC644330	rs1859962 rs887391	1.21 1.14	1.12 1.08	1.3 1.2	8.E-07 7.E-07	<0.001 <0.001	0.161 0.356	<0.001 <0.001	0.318 0.362

Abbreviations: CI, confidence intervals; FPRP, false-positive report probabilities; OR, odd ratios. FPRPs in bold indicate values that are \leq 0.2 and are therefore considered noteworthy. Table does not include associations for which FPRPs could not be calculated due to missing ORs and CIs. a'Dong' indicates variants reported in previous systematic review of meta-analyses (Dong *et al*⁸). ^bItalicized *P*-values indicate those derived from calculation using methods described in Wacholder *et al*.¹² All other values are as reported in source noted.




Figure 2 Odds ratios of variants common to candidate gene meta-analyses or pooled analyses (MA) and GWAS excluding *ALDH2* in esophageal cancer (meta-analysis OR = 2.52, GWAS OR = 3.48).

the mutation was not discovered by candidate gene methods but by studying families with Li–Fraumeni syndrome.²⁰ As in candidate gene studies, inadequate sample size should also be considered as a possible source of insufficient power. Significant positive correlations have been noted between the number of novel SNPs detected and the sample size of GWAS.²¹

In our study, the 41 associations common to both meta-analysis and GWAS had effect sizes that were generally similar and mostly small. A notable outlier is the association of *ALDH2* rs671 risk for esophageal cancer, which has been described by three meta-analyses and one GWAS since 2000. *ALDH2* encodes a key enzyme in the metabolism of consumed alcohol, which is a major epidemiologic risk factor for esophageal cancer. A 2009 paper by Khoury and Wacholder notes that very few association studies have considered gene– environment interactions, and that incorporating both genetic and environmental factors in the analysis may be one path to finding additional associations and larger effect sizes but may require extremely large sample sizes to achieve sufficient power.²² Other methodological challenges unique to genome-wide environmental interaction studies exist, which can perhaps explain the low number of publications in this field.²³

Our analysis had some limitations. By considering only metaanalyses of candidate genetic associations, we could have left out some recent individual candidate gene studies with sufficiently large sample sizes to find noteworthy associations. By considering only the main associations in candidate gene meta-analyses, we could have overlooked important subgroup associations, such as some that seem to be race- or ethnicity-specific associations.²⁴ We also did not use linkage disequilibrium between markers when defining indirect overlap but relied on physical distance. It is known that linkage disequilibrium and physical distance are correlated.²⁵ Markers that are located close to each other generally exhibit higher linkage disequilibrium than those that are located further apart. Although a distance of 1 Mb may be considered large for identifying overlapping associations, at least one GWAS has traced an association to a causal variant located at roughly this distance away from the original signal.²⁶ It should also be noted that reducing this distance would not change our conclusion that there is limited overlap between the two study types. Finally, we attempted to avoid duplication of cases by limiting our analysis to only the most recent meta-analysis and GWAS for each association. Nevertheless, this possibility cannot be completely excluded, especially because GWAS are often assembled from previously ascertained groups of cases and controls.

One criticism of candidate gene studies is that most genetic associations are not replicated in subsequent studies.² Similar to GWAS, findings from the candidate gene studies must demonstrate replication to be considered valid. Meta-analysis of the published literature is an important tool in assessing the cumulative evidence on genetic associations.²⁷ Consortia offer another approach to metaanalysis that may help protect against the effects of selective reporting and publication bias. In a study comparing meta-analyses of individual case-control studies with consortium analyses in breast cancer, the authors concluded that meta-analyses and consortia-wide analyses were complementary.²⁸ Consortium-based analyses may be particularly useful for detecting variants modified by weak-tomoderate gene-environment interactions.²⁹ Meta-analysis has also become increasingly popular in GWAS,³⁰ where it can aid in exploring the heterogeneity across data sets and identifying more disease-related genes.³¹ In 2011, there were 173 publications on metaanalyses and pooled analyses of candidate genes in cancer, and 39 GWAS, of which 6 included a meta-analysis.9

In light of improved genetic sequencing technologies, some discussions on the future roles of GWAS and candidate gene studies are appropriate. One of the limitations of current GWAS technology is its limited ability to detect low-frequency variants. A study by Siu *et al*³² found that GWAS coverage of rare variants was still inadequate despite using chips designed to detect them. In addition, the quality of imputed low-frequency and, especially, rare variants in these studies is generally lower than that for common variants.³³ Still, arrays and reference panels have improved much since the advent of GWAS, the most recent of which was not included in our analysis. It has been estimated that previous GWAS have detected less than 20% of all independent GWAS-detectable SNPs in chronic diseases, but future GWAS can potentially detect more SNPs through improved coverage and, especially, sample sizes.²¹

Studies that use recently developed arrays such as MetaboChip,³⁴ ImmunoChip,³⁵ and iCOGS array³⁶ represent the latest reinvention of the candidate gene study. These chips can contain hundreds of thousands of SNPs that were chosen for replicating and fine-mapping loci identified from GWAS, as well as to cover the most promising candidate genes. A recent consortium-based meta-analysis that used the iCOGS array identified 23 new prostate cancer susceptibility loci.³⁷ Next-generation sequencing is also increasingly helping to improve the understanding of genetic association studies.³² Projects such as ENCODE are likely to provide new insights into GWAS associations in non-coding regions of the genome.³⁸ Together, these multiple approaches will help us identify additional genetic associations and understand their functional implications.

CONFLICT OF INTEREST

The authors declare no conflicts of interests. The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the Department of Health and Human Services.

ACKNOWLEDGEMENTS

We would like to acknowledge the contributions of Camilla Marie Benedicto, for her role in the initiation of this analysis and Tram Kim Lam, Elizabeth M Gillanders, and Carolyn M Hutter for their thoughtful comments on the manuscript.

- GWAS and candidate gene meta-analyses CQ Chang et al
- 1 Cordell HJ, Clayton DG: A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in type 1 diabetes. *Am J Hum Genet* 2002; **70**: 124–141.
- 2 Tabor HK, Risch NJ, Myers RM: Candidate-gene approaches for studying complex genetic traits: practical considerations. *Nat Rev Genet* 2002; **3**: 391–397.
- 3 Ioannidis JP, Gwinn M, Little J *et al*: A road map for efficient and reliable human genome epidemiology. *Nat Genet* 2006; **38**: 3–5.
- 4 Hindorff LA, Gillanders EM, Manolio TA: Genetic architecture of cancer and other complex diseases: lessons learned and future directions. *Carcinogenesis* 2011; 32: 945–954.
- 5 Hardy J, Singleton A: Genomewide association studies and human disease. N Engl J Med 2009; 360: 1759–1768.
- 6 Witte JS: Genome-wide association studies and beyond. *Ann Rev Public Health* 2010; **31**: 9–20, 4 p following 20.
- 7 Freedman ML, Monteiro AN, Gagther SA et al: 'Principles for the post-GWAS functional characterization of cancer risk loci.'. Nat Genet 2011; 43: 513–518.
- 8 Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U: Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. *JAMA* 2008; 299: 2423–2436.
- 9 Schully SD, Yu W, McCallum V et al: Cancer GAMAdb: database of cancer genetic associations from meta-analyses and genome-wide association studies. Eur J Hum Genet 2011; 19: 928–930.
- 10 Lin BK, Clyne M, Walsh M *et al*: Tracking the epidemiology of human genes in the literature: the HuGE Published Literature database. A J Epidemiol 2006; 164: 1–4.
- 11 Hindorff LA, Sethupathy P, Junkins HA et al: Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 2009; 106: 9362–9367.
- 12 Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N: Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434–442.
- 13 Theodoratou E, Montazeri Z, Hawken S et al: Systematic meta-analyses and field synopsis of genetic association studies in colorectal cancer. J Natl Cancer Inst 2012; 104: 1433–1457.
- 14 Johansen CT, Wang J, McIntyre AD et al: Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia. Circ Cardiovasc Genet 2012; 5: 66–72.
- 15 Panagiotou OA, Ioannidis JP: What should the genome-wide significance threshold be? Empirical replication of borderline genetic associations. Int J Epidemiol 2012; 41: 273–286.
- 16 Li MX, Yeung JM, Cherny SS, Sham PC: Evaluating the effective numbers of independent tests and significant p-value thresholds in commercial genotyping arrays and public imputation reference datasets. *Hum Genet* 2012; **131**: 747–756.
- 17 Barrett JC, Cardon LR: Evaluating coverage of genome-wide association studies. Nat Genet 2006; 38: 659–662.
- 18 Michel S, Liang L, Depner M et al: Unifying candidate gene and GWAS approaches in asthma. PloS ONE 2010; 5: e13894.

- 19 Einarsdottir K, Humphreys K, Bonnard C et al. Linkage disequilibrium mapping of CHEK2: common variation and breast cancer risk. PLoS Med 2006; 3: e168.
- 20 Bell DW, Varley JM, Szydlo TE et al: Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286: 2528–2531.
- 21 Lindquist KJ, Jorgenson E, Hoffmann TJ, Witte JS: The impact of improved microarray coverage and larger sample sizes on future genome-wide association studies. *Genet Epidemiol* 2013; **37**: 383–392.
- 22 Khoury MJ, Wacholder S: Invited commentary: from genome-wide association studies to gene-environment-wide interaction studies—challenges and opportunities. Am J Epidemiol 2009; 169: 227–230, discussion 234–235.
- 23 Aschard H, Lutz S, Maus B et al: Challenges and opportunities in genome-wide environmental interaction (GWEI) studies. Hum Genet 2012; 131: 1591–1613.
- 24 Garte S: The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. *Carcinogenesis* 1998; **19**: 1329–1332.
- 25 Abecasis GR, Noguchi E, Heinzmann A et al. Extent and distribution of linkage disequilibrium in three genomic regions. Am J Hum Genet 2001; 68: 191–197.
- 26 Germain M, Saut N, Oudot-Mellakh T et al: Caution in interpreting results from imputation analysis when linkage disequilibrium extends over a large distance: a case study on venous thrombosis. PLoS ONE 2012; 7: e38538.
- 27 Ioannidis JP, Boffetta P, Little J et al: Assessment of cumulative evidence on genetic associations: interim guidelines. Int JI Epidemiol 2008; 37: 120–132.
- 28 Janssens AC, Gonzalez-Zuloeta Ladd AM, Lopez-Leon S et al: An empirical comparison of meta-analyses of published gene-disease associations versus consortium analyses. *Genet Med* 2009; 11: 153–162.
- 29 Nickels S, Truong T, Hein R et al: Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet 2013; 9: e1003284.
- 30 Yesupriya A, Yu W, Clyne M, Gwinn M, Khoury MJ: The continued need to synthesize the results of genetic associations across multiple studies. *Genet Med* 2008; 10: 633–635.
- 31 Zeggini E, Ioannidis JP: Meta-analysis in genome-wide association studies. *Pharma-cogenomics* 2009; 10: 191–201.
- 32 Siu H, Zhu Y, Jin L, Xiong M: Implication of next-generation sequencing on association studies. BMC Genomics 2011; 12: 322.
- 33 Machiela MJ, Chen C, Liang L et al: One thousand genomes imputation in the national cancer institute breast and prostate cancer cohort consortium aggressive prostate cancer genome-wide association study. Prostate 2012; 73: 677–689.
- 34 Voight BF, Kang HM, Ding J et al: The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet 2012; 8: e1002793.
- 35 Cortes A, Brown MA: Promise and pitfalls of the immunochip. Arthritis Res Ther 2011; 13: 101.
- 36 Bahcall OG: iCOGS collection provides a collaborative model. *Nature Genet* 2013; **45**: 343.
- 37 Eeles RA, Olama AA, Benlloch S *et al*: Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. *Nature Genet* 2013; 45: 385–391.
- 38 Kilpinen H, Barrett JC: How next-generation sequencing is transforming complex disease genetics. *Trends Genet* 2013; 29: 23–30.

Supplementary Information accompanies this paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)